EGFR and neoplasm: As stated above, liquid biopsy can be utilized to dynamically detect resistance mutations in course of treatment with EGFR inhibitors and, when the tumor tissue biopsy is not possible, ctDNA analysis is the only available method for the identification of patients that can benefit from a TKI therapy.